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Jacques Delaunay,1 Sameh Ayari,1 Viviane Dubruille,1 Steven Le Gouill,1,2 Beatrice Mahe,1
Thomas Gastinne,1 Nicolas Blin,1 Beatrice Saulquin,1 Jean-Luc Harousseau,1,2
Philippe Moreau,1,2 Mohamad Mohty1,2,3Unrelated umbilical cord blood (UCB) is being increasingly used as an alternative stem cell source for allo-
geneic stem cell transplantation (allo-SCT). This retrospective study assessed infectious complications
occurring in adult patients after UCB transplantation (UCBT). 31 patients received a single (n54) or double
UCBT (n527) with a median dose of 4.7107 nucleated cells/kg (range: 2.4-7.7). Patients received either
a reduced-intensity conditioning (RIC; n523) or a standard myeloablative (MA) regimen (n58). The cumu-
lative incidence of neutrophil recovery was 90%. Neutrophil recovery was achieved at a median time of 24
(range: 8-60) days after UCBT. The cumulative incidences of bacterial, fungal, and parasitic infections were,
respectively, 16%, 10%, and 6%. Bloodstream infections were neither lethal nor required any intensive care
therapy. Similarly, invasive fungal infections and parasitic infections did not cause any death in those patients
with sustained engraftment. Although the cumulative incidence of cytomegalovirus (CMV) recurrence was
21%, no CMV disease was observed. With a median follow-up of 10 (range: 3-30) months, 10 patients
have died (relapse, n55; nonrelapse mortality, [NRM] n55). Overall, the cumulative incidence of infec-
tious-related mortality (IRM) was 8%. In conclusion, this data suggests that UCBT can be performed in adult
patients with hematologic malignancies with an acceptable incidence of IRM provided a sufficient dose of
nucleated cells is infused to the patient.
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The majority of adult patients with hematologic
malignancies requiring allogeneic stem cell transplan-
tation (allo-SCT) lack a matched related donor [1].
The search for an HLA-matched unrelated donor
(MUD) used to be the only possibility to proceed to
allo-SCT. Unrelated umbilical cord blood (UCB) is
now being increasingly used as an alternative stem
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cies, UCB cells exhibit an immunologic activity against
neoplastic cells, a phenomenon known as the graft-
versus-tumor (GVT) effect [2-5]. However, like with
other stem cell sources, this GVT effect can be offset
by a significant incidence of non-relapse mortality
(NRM). Most of the time, NRM originates from graft
failure, graft-versus-host disease (GVHD), or infec-
tions [6]. Initial studies depicted a high rate of severe
or fatal infections among UCB transplant recipients
[7,8], especially in adult patients [9]. However,
more recent studies reported an infectious-related
mortality (IRM) incidence similar to that of allo-
SCT using HLA-MUD [10]. These conflicting results
highlight the need for a thorough assessment of
infectious complications after UCB transplantation
(UCBT) toward improving patients’ outcome. The
aim of this retrospective analysis was to define the
incidence and features of opportunistic infectious
complications in a series of 31 adult patients who
received UCBT, and to assess its impact on clinical
outcome.1531
Table 1. Patients’ Characteristics
Characteristics N (%)
N 31
Median age (range) 47 (20-63)
Recipient sex male 13 (42%)
Weight, kg (range) 63 (47-103)
Diagnosis and status
at transplant
ALL: 7 CR: 5
PD: 2
AML: 8 CR: 7
Refractory: 1
CLL: 2 CR: 1
PR: 1
NHL: 8 CR: 2
PR: 5
Relapse: 1
MDS: 3 Upfront: 2
Secondary graft failure: 1
MPD: 2 Upfront: 2
Previous transplant Auto-SCT: 7
Allo-SCT: 3
Recipient CMV serology Positive: 12
Negative: 19
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lym-
phoma; MDS, myelodysplasia; MPD, myeloproliferative disorder; CR,
complete response; PR, partial response; PD, progressive disease.
Table 2. UCBT Procedures
Number of CBTunits Single: 4
Double: 27
HLA matching Single: 6/6: 0
5/6: 1
4/6: 3
Double: 6/6 and 6/6: 1 5/6 and 5/6: 13
6/6 and 5/6: 0 5/6 and 4/6: 6
6/6 and 4/6: 0 4/6 and 4/6: 7
Total nucleated
cells$107/kg*
4.7 (2.4-7.7)
CD34+$105/kg* 1.4 (0.5-3.6)
Conditioning regimen Reduced-intensity conditionning: 23
Myeloablative: 8
GVHD prophylaxis CsA-Mycophenolate mofetil: 27CSA-CT: 4
Steroids ($2mg/kg) 7
GVHD indicates graft-versus-host disease; CsA, cyclosporine; CBT,
cord blood transplantation; UCBT, umbilical cord blood transplantation.
Conditioning regimens included: fludarabine (Flu) (200 mg/m2), Cyclo-
phosphamide (Cy) (50 mg/kg), total body irradiation (TBI) (2 gy)6ATG
(n518); F (150 mg/m2)-Cy (100 mg/kg)-ATG (5 mg/kg) (n53); F (120
mg/m2)-Cy (1200 mg/m2)-TBI (2 gy)-ATG (7.5 mg/kg) (n51); Clofara-
bine (150 mg/m2)-AraC 5000 mg/m2-Cy (60 mg/kg)-Bu (6.4 mg/kg)-
ATG (5 mg/kg) (n51); Cy (120 mg/kg)-TBI (12 gy) (n57); Bu (orally)
(16 mg/kg)-Cy (120 mg/kg) (n51).
*Before thawing. In case of double UCBT, addition of cell numbers of
UCB1 and UCB2.
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Study Design
This was a retrospective analysis of 31 consecutive
patients treated between February 2003 and October
2008, in a single institution (University-Hospital of
Nantes, Nantes, France). Patients’ characteristics are
detailed in Table 1. During this study period, UCBT
was performed in those patients lacking an HLA-
matched related or unrelated donor.Written informed
consent was obtained from each patient. The study was
performed according to institutional guidelines. HLA
A,B serologic typing andDRB1high-resolution typing
were performed for both patients and UCB units.
Selected UCB units displayed a 4/6, 5/6, or 6/6 HLA
donor-recipient matching. In 27 of 31 cases, and as
per institutional guidelines, 2 UCB units were used to
increase the total number of nucleated cells (TNC)
infused to the patient (target TNC .2.5107/kg).Transplant Procedures and Graft
Characteristics
Transplant procedures are summarized in Table 2.
Patients received either a reduced-intensity condition-
ing (RIC) regimen (n523) or a standard myeloablative
(MA) regimen (n58). The choice between a standard
MA or an RIC regimen was based on patients’ age
and comorbidities as previously described [11]. To ac-
celerate engraftment, all patients received granulocyte
colony-stimulating factor (G-CSF) starting from day 5
after UCB infusion. GVHD prophylaxis included cy-
closporine (CsA) and mycophenolate mofetil (MMF;1000 mg/12 hours; n527) or CsA in combination
with corticosteroids (2 mg/kg/day; n54). Chimerism
was determined from nucleated blood cells or
CD31-T cell fraction as previously described [12]. In
the absence of GVHD, MMF and CsA were progres-
sively decreased starting from day 160 and day 1120
after UCBT, respectively.
Infection Prophylaxis, Monitoring, and
Supportive Care
Allo-SCTwas performed in roomswith laminar air
flow devices. All blood products were leukocyte-de-
pleted and irradiated before transfusion. No antibacte-
rial prophylaxis was delivered prior to engraftment.
Fluconazole (400 mg/day) and valacyclovir (500 mg
2/day) were given to all patients starting from day 0.
Amoxicillin or penicillin was used after neutrophil re-
covery to prevent encapsulated bacterial infections.
Similarly, cotrimoxazole prophylaxis against Pneumo-
cystis jiroveci and toxoplasmosiswas started after neutro-
phil recovery. Cytomegalovirus (CMV), Epstein-Barr
virus (EBV), adenovirus, and Human Herpes Virus 6
(HHV6) were routinely screened by quantitative
polymerase chain reaction (PCR). CMV reactivation
was defined as a positive PCR $1000 copies/106 cells.
Adenovirus was documented in the stools and on gut
biopsies. Galactomannan antigen was tested twice
a week to detect Aspergillosis species (Aspergillus sp.). In
the case of positive Galactomannan test or any respira-
tory symptom, a thoracic computed tomography (CT)
scan and/or a respiratory endoscopy with bronchoal-
veolar lavage (BAL) were performed. If temperature
was $38.3C, $38C for 1 hour, or patient showed
Biol Blood Marrow Transplant 15:1531-1537, 2009 1533Infectious Complications after UCBTany sign of infection, blood and fungal cultures were
performed and broad-spectrum antibiotics were
administered. For the purpose of this analysis, and
except for coagulase negative staphylococci and cory-
nebacteria, all positive blood cultures were recorded.
In the case of persistent fever and prolonged neutrope-
nia, an antifungal therapywas empirically added. Prob-
able or proved aspergillosis was classified according to
Ascioglu et al. [13]. Invasive aspergillosis was treated
primarily with voriconazole. In the case of positive
CMV detection, preemptive therapy with ganciclovir
was started as soon as the viral load was $1000 cop-
ies/106 cells. In the case of rising or persistent CMV in-
fection after 5 to 7 days of ganciclovir preemptive
therapy, patients were switched to foscarnet therapy
(180 mg/kg/day) for 14 days. Patients did not receive
systematic maintenance therapy after preemptive ther-
apy. CMV disease was defined as described previously
[14]. After discharge, patients received routine prophy-
lactic i.v. immunoglobulins.Statistical Analysis
All time-related data were measured from the day
of UCBT. Complete remission (CR) and overall sur-
vival (OS) were defined according to standard criteria,
and OS was estimated with the Kaplan-Meier method.
NRM and IRM were evaluated using the cumulative
incidence method [15]. Neutrophil recovery was de-
fined as the first of 3 consecutive days with neutrophils
$0.5109/L. Partial and complete neutrophil engraft-
ments were defined as neutrophil recovery with donor
chimerism $10% and $90%, respectively. Engraft-
ment was calculated by cumulative incidence evalua-
tion using death without engraftment as a competing
event. All data were computed using the R package
(R Development Core Team, 2006. R: A language
and environment for statistical computing. R Founda-
tion for Statistical Computing, Vienna, Austria. ISBN
3-900051-07-0, URL http://www.R-project.org).RESULTS
Engraftment
The cumulative incidence of neutrophil recovery
was 90% (n528). Neutrophil recovery was achieved
at a median time of 24 (range: 8-60) days after
UCBT. Platelet recovery .20109/L was achieved
in 26 patients (cumulative incidence, 84%) at a median
time of 43 (range: 0-176) days after UCBT. Partial and
complete engraftment occurred in 22 and 20 patients,
respectively (CI: 71% and 64%, respectively). Among
the 9 patients with primary graft failure, 5 patients ex-
perienced spontaneous autologous recovery, 1 patient
was successfully rescued by autologous bone marrow
(BM; auto-SCT), and 3 patients remained withoutany neutrophil recovery. Two secondary graft failures
were observed, 1 of which had spontaneous autologous
recovery.Survival and Causes of Death
With a median follow-up of 10 (range: 3-30)
months in surviving patients, the OS was 57% (95%
CI, 38-84). At last follow-up, 10 patients have died.
Relapse (n55) and NRM (n55) were the primary
causes of death. In the 5 patients who died from
NRM, the causes of death were secondary graft failure
(n51), refractory GVHD (n52) and infectious-related
mortality (n52; cumulative incidence, 8%; Figure 1A).
The 2 patients who died from infectious causes had an
EBV-related lymphoproliferative disorder and adeno-
virus infection, respectively.Features of Bacteremia
Overall, 7 documented bacteremia were observed
in 5 patients, at a median time of 7 (range: 3-277)
days after UCBT (Table 3). The isolated bacteria
included Streprococcus mitis (n53), Stapylococcus aureus
(n51), Escherichia coli (n51), Enterobacter cloacae
(n51), and Pseudomonas aeruginosa (n51). Of note,
none of these bacteria had been isolated from the
same patient prior to UCBT. The cumulative
incidence of first bacteremia was 16% (Figure 1B) in
the whole study population and 21% (n54/20) when
excluding patients with graft failure. Except for 1
patient with relapsed acute myelogenous leukemia
(AML), these bacteremia were neither fatal nor
required a transfer into the intensive care unit (ICU).Viral Infections
Recurrent CMV infection was detected in 6 pa-
tients at a median time of 36 (range: 26-89) days. No
CMV disease developed after preemptive CMV ther-
apy. The cumulative incidence of recurrent CMV in-
fection was 21% (Figure 1C). Of note, 4 of these 6
cases of CMV recurrences were diagnosed in patients
with primary graft failure. Therefore, the cumulative
incidence was only 11% when focusing on patients
without graft failure. EBV reactivation occurred in 6
patients with a median time of 101 (range: 28-438)
days after UCBT. Except for 1 patient who developed
a fatal EBV-related lymphoproliferative disorder
refractory to Rituximab, all other 5 cases of EBV infec-
tions were asymptomatic. Other isolated viruses
included: BK-virus with hemorrhagic cystitis (n56),
adenovirus (detected in the blood, n53), varicella-
zoster virus (VZV; n51), respiratory syncytial virus
(RSV; rhinitis, n51), and parainfluenzae 3 virus (rhini-
tis, n51). Of note, HHV6 was systematically detected
in recipient blood samples. Except for the 2 fatal cases
with EBV-related lymphoproliferative disorder and
Figure 1. Cumulative incidence of infectious-related mortality (A), bacteremia (B), CMV recurrence (C), and invasive fungal infections (D).
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viral infections did not require transfer into the ICU.
Fungal and Parasitic Infections
In all, 5 cases of fungal or parasitic infections were
documented. Two cases of Toxoplasmosis gondii
encephalitis were diagnosed in 1 patient with a primary
graft failure and in another patient with a secondary
graft failure (cumulative incidence of parasitic infec-
tions, 6%). Three probable pulmonary invasive asper-
gillosis were also diagnosed, 2 of which occurred in
patients with refractory acute leukemias. The cumula-
tive incidence of invasive fungal infections (IFI) was
10%. None of these fungal or parasitic infections was
the primary cause of death.DISCUSSION
In the current study, we report the incidence and
features of infectious complications occurring in ourfirst series of 31 adult patients receiving UCBT.
Overall, IRM was relatively low (8%), and was exclu-
sively because of viral agents. Such low incidence of
IRM is somewhat at odd with the initial series
reporting UCBT in adult patients [6-9]. The high
TNC doses used in our study (almost all patients re-
ceived TNC.2.5107/kg) might explain this discrep-
ancy, at least in part. Indeed, and although not
statistically significant, based on the median number
of TNC, the cumulative incidence of bacteremia,
parasitic, or invasive fungal infections was higher in
patients transplanted with TNC #4.7107/kg com-
pared to patients receiving TNC .4.7107/kg (44%
versus 20%; P5.17; Figure 2). In previous studies as-
sessing UCBT outcome in adult patients, patients
used to be transplanted with lower numbers of TNC,
a parameter that has been shown to a be major prog-
nostic factor in UCBT [10,16,17]. To circumvent the
inconvenience of a lower TNC, a majority of the pa-
tients (87%) included in this study, received double
UCBT [18].
Table 3. Isolated Microorganisms after UCBT
No.
TNC
(107/kg)
Toxoplasmosis
Serology
Recipient/Donor
Primary Cause
of Death
Secondary
Cause of Death
Bacteraemia*
(Day)
Other Bacterias,
Site (Day) Viruses (Day) Fungi/Parasites (Day)
1 2.40 +/2 R/PD CMV recurrence (26)
2 2.80 +/+ R/PD PIPA BK (20) PIPA (10)
3 3.49 +/2 BK (33)
CMV recurrence (37)
T. gondii, CNS (26)
4 3.58 NE/2 R/PD E. coli E. cloacae (173)
E. coli (277)
E. coli, CVC (173)
5 3.88 +/+
6 4.00 +/+
7 4.00 2/2
8 4.04 NE/2 Graft failure T. gondii BK (5) T. gondii, CNS (54)
9 4.04 +/+
10 4.12 2+ E. coli, cystitis (54)
11 4.23 +/+ IRM (EBV) BK (64)
CMV recurrence (89)
EBV-rel LPD (275)
PIPA (1)
12 4.26 2/+
13 4.54 +/+ P. aeruginosa (3) C. difficile, gut (6)
14 4.62 2/+ EBV recurrence (29)
15 4.69 2/2 GVHD P. aeruginosa S. mitis (4)
S. aureus (238)
P. aeruginosa, bronchi (507) Adenovirus (80)
16 4.70 +/2 GVHD P. mirabilis, cystitis (52)
E. coli, cystitis (73)
BK (51)
17 4.71 +/+ VZV(435)
EBV recurrence (438)
18 4.81 2/+
19 4.98 2/2 S. mitis (7) Adenovirus (79)
20 4.98 +/+ CMV recurrence (34)
21 5.04 +/+ CMV recurrence (45)
22 5.16 2+
23 5.16 2/+ EBV recurrence (28)
24 5.20 2/+ IRM (adenovirus) Adenovirus (63)
25 5.35 2/2
26 5.42 +/2
27 5.46 +/+ SRV (34)
BK (38)
EBV recurrence (117)
Parainfl. virus 3 (161)
28 5.49 +/+
29 5.82 +/2 R/PD S. mitis (4)
30 7.06 NE/+ R/PD CMV recurrence (35) PIPA (61)
31 7.68 2/2 EBV recurrence (85)
E. coli indicates Escherichia coli; C. difficile, Clostridium difficile; E. cloacae, Enterobacter cloacae; P. mirabilis, Proteus mirabilis; P. aeruginosa, Pseudomonas aeruginosa; S. mitis, Streptococcus mitis; CMV, cytomegalovirus; EBV,
Epstein-Barr virus; LPD, lymproliferative disorder; VZV, Varicella-Zona-virus; Parainfl. Virus, Parainfluenzae virus; PIPA, probable invasive pulmonary aspergillosis; T. gondii, Toxoplasmosis gondii; SRV, human respiratory
syncytial virus; NE, not evaluated; CVC, central venous catheter; CNS, central nervous system.
For toxoplasmosis serology, in case of double UCBT, the donor was considered as positive if at least one of the CB units was from a positive donor.
*Two patients had catheter related-infections with documentation of Staphylococcus epidermidis at day +18 and at day +6 and +70.
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Figure 2. Cumulative incidence of bacteremia, parasitic, or invasive
fungal infections in patients grafted with TNC #4.7107/kg (dashed
line) or TNC .4.7107/kg (solid line).
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lated and unrelated donors, the transplant period is
classically divided into 3 phases. The first phase is
related to the aplastic period, with neutropenia and
toxicity of the conditioning regimen favoringamajority
of bacterial infections, but also favoring fungal infec-
tions [19]. The second phase is characterized by neu-
trophil recovery, but with a major T cell dysfunction
because of the immunosuppressive therapies used for
acute GVHD (aGVHD) management and thus favor-
ing viral infections, especially CMV [19]. A third phase
might develop in some long-term surviving patients
with several complex immune dysfunctions because of
chronic GVHD (cGVHD) and/or prolonged immu-
nosuppression [19]. Findings from our study are in
line with such pattern, because bacteremia occurred
mainly in the early period afterUCBT [20-22].Despite
the lack of antibiotic prophylaxis during the aplastic
period, bacteremia was not the primary cause of death
in any patient. This is all the more important as vanco-
mycin or fluoroquinolones prophylaxis may trigger the
emergence of bacterial resistance such as vancomycin-
resistant Enterococcus or fluoroquinolone-resistant
Escherichia coli [19]. Similarly, fungal infections did
not cause any death in patients with sustained neutro-
phil recovery. However, because of the low number
of events, one cannot exclude that some prophylaxis
with drugs such as voriconazole might be needed in
patientswith prolonged neutropenia to decrease the in-
cidence of invasive aspergillosis as previously reported
by Miyakoshi et al. [23].
In terms of viral infections, CMV reactivation was
regularly detected in UCBT recipients but preemptive
therapy efficiently prevented the onset of CMV dis-ease. As it is the case for bacterias, the overuse of pro-
phylactic (val)ganciclovir may potentially trigger the
emergence of ganciclovir-resistant strains of CMV.
Our results suggest that CMV prophylactic treatment
is not mandatory in UCBT recipients. However, we
could document a relatively higher incidence of other
viral infections such as BK-virus, EBV, or adenovirus.
Of note, 2 EBV and adenovirus cases were fatal despite
regular and close patient monitoring. In addition, the
HHV6 virus was almost systematically detected in
blood samples from all patients, but without clinical
manifestations, highlighting the need for prospective
studies focusing on such emergent viruses in the field
of allo-SCT. Indeed, delayed immune recovery has
been already shown to be a major limitation after
UCBT [24]. Such delayed immune recovery would fa-
vor the emergence of opportunistic viral infections fur-
ther enhancing the need for a stringent biologic
monitoring for assessment of the potential differences
between UCBT and allo-SCT using conventional do-
nors. Such biologic monitoring would also pave the
way for the use of newer cytokines such as IL-7 or
IL-15 toward enhancing the kinetics of immune recov-
ery after UCBT [25-26].
In addition to its obvious limitations in terms of
cohort size and follow-up, bloodstream and fungal
infections may have been underestimated because of
the use of empirical broad-spectrum antibiotics and
antifungal therapy before neutrophil recovery. In this
respect, broad-spectrum b-lactamins, glycopeptides,
and antifungal agents (caspofungin or liposomal
amphotericin B) were empirically administered to
87%, 76%, and 50% of patients, respectively. Also,
bacterial and fungal infections usually vary depending
on the local microbial ecology.
Overall, and in contrast to the common belief, our
study suggests that IRM is not excessively high after
UCBT provided a sufficient dose of TNC is infused
to the patient. Life-threatening infections do still
occur, especially in patients with severe GVHD or
those patients with primary or secondary graft failure,
underlining the need for prospective efforts to develop
optimal antimicrobial preventive strategies in such
challenging situations. However, close monitoring,
broad screening of the different opportunistic micro-
bial agents, and adhering to the guidelines of the
CDC, the Infectious Diseases Society of America,
and the American Society of Blood and Marrow
Transplantation [19] should reduce the severity of
opportunistic infections among UCBT recipients,
prevent the emergence of microbial resistance, and
would allow for early diagnosis and efficient treatment.ACKNOWLEDGMENTS
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